We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 25, 2017

Lapatinib in Combination With Foretinib in HER2-Positive Metastatic Breast Cancer

Breast Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research
A Phase-I Study of Lapatinib in Combination With Foretinib, a c-MET, AXL and Vascular Endothelial Growth Factor Receptor Inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER-2)-Positive Metastatic Breast Cancer
Breast Cancer Res 2017 May 02;[EPub Ahead of Print], SK Chia, SL Ellard, M Mates, S Welch, C Mihalcioiu, WH Miller, K Gelmon, C Lohrisch, V Kumar, S Taylor, L Hagerman, R Goodwin, T Wang, S Sakashita, MS Tsao, E Eisenhauer, P Bradbury

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading